Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice

@article{Becquemont2008EvidenceFA,
  title={Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice},
  author={Laurent Becquemont},
  journal={European Journal of Clinical Pharmacology},
  year={2008},
  volume={64},
  pages={953-960}
}
Oral anticoagulants (OA) are a leading cause of fatal haemorrhagic adverse events in relation with an important interindividual variability of response to these drugs. Besides several clinical factors, this interindividual variability of response to OA has a pharmacogenetic basis. Carriers of cytochrome P450 2C9 (CYP2C9)-deficient alleles have a reduced clearance of warfarin and are exposed to dramatic overdoses in the first weeks of treatment. Genetic polymorphisms of vitamin K epoxide… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 72 REFERENCES

Similar Papers

Loading similar papers…